TAS-120-202

A phase 2 study of Futibatinib in Patients With Specific FGFR Aberrations

Study TAS-120-202 is an open-label, multinational, 3-arm Phase 2 study evaluating the efficacy, safety, tolerability, PK, and pharmacodynamics of futibatinib in patients with FGFR aberrations. Eligible patients will be assigned to 1 of 3 treatment cohorts based on diagnosis and FGFR gene aberration status.

This is currently open and recruiting at the following UK location:

Sarah Cannon Research Institute UK
London, W1G 6AD
Contact: Dr Hendrik-Tobias Arkenau:
tobias.arkenau@hcahealthcare.co.uk

And due to open soon at following UK location:
Addenbrooke’s Hospital,
Cambridge
Contact: Dr Richard Baird:
rdb39@medschl.cam.ac.uk

For more details on the trial, and for other locations including European, go to: https://clinicaltrials.gov/ct2/show/NCT04189445

Sponsor: Taiho Oncology